-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

166 Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Lymphoma
Hematology Disease Topics & Pathways:
Biological therapies, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Therapies
Saturday, December 10, 2022: 12:45 PM

Roch Houot1*, Emmanuel Bachy, MD, PhD2*, Guillaume Cartron, MD, PhD3*, François-Xavier Gros4*, Franck Morschhauser, MD, PhD5*, Lucie Oberic, MD6*, Thomas Gastinne, MD7*, Pierre Feugier, MD8*, Remy Dulery9*, Catherine Thieblemont, MD, PhD10, Magalie Joris, MD11*, Francisco Llamas-Gutierrez12*, Emmanuel Itti, MD, PhD13*, Cedric Menard14*, Yassine Al-Tabaa15*, Clement Bailly16*, Marie-Helene Delfau17*, Camille Laurent, MD, PhD18* and Francois Lemonnier19*

1CHU de Rennes, Université de Rennes, INSERM U1236, EFS, Rennes, France
2Department of Hematology, Lyon-Sud Hospital, Pierre-Benite, France
3Département d'Hématologie clinique, CHU de Montpellier, Montpellier, France
4Hopital Du Haut-lévèQue, Pessac, FRA
5Hematology Department, Lille University Hospital, Lille, France
6Department of Hematology, Institut Universitaire Cancerologie Toulouse-Oncopole, Toulouse, France
7Hematology Department, Nantes University Hospital, Nantes, France
8Department of Hematology, Henri Poincaré University, CHU NANCY BRABOIS, Vandoeuvre Les Nancy, France
9Saint-Antoine Research Center, Inserm UMR938, Sorbonne Université, Paris, France
10Hôpital Saint-Louis, Paris, France
11Service d’Hématologie Clinique et Thérapie cellulaire, Centre Hospitalier Universitaire d’Amiens, Amiens, France
12Hemopathology lab, University hospital of Rennes, Rennes, France
13Nuclear Medicine, Henri Mondor Hospital, Créteil, France
14SITI laboratory, University Hospital Pontchaillou, Rennes, France
15Scintidoc Nuclear Medicine Center, Montpellier, France
16Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, Nantes, France
17Department of Immunology, University Hospital, Creteil, France
18Institut universitaire du cancer Toulouse-Oncopole CHU Toulouse, Toulouse, France
19Unité Hémopathie Lymphoïde, Hôpital Henri Mondor & Université Paris Est Créteil, Créteil, France

Background

Patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after first-line treatment who are unable to undergo high-dose chemotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) have poor outcomes and limited treatment options. Axicabtagene ciloleucel (axi-cel) has recently demonstrated superiority over standard of care (SOC; salvage chemotherapy followed by HDCT/HSCT in responders) as second-line therapy in patients intended for transplant in the phase 3, ZUMA-7 study (Locke et al, NEJM 2022). The objective of the open-label, phase 2, ALYCANTE study (NCT04531046) was to evaluate the efficacy and safety of axi-cel in patients with R/R LBCL after 1 prior line of therapy not intended for HDCT/HSCT owing to age and/or comorbidities.

Methods

Eligible patients were adults with R/R LBCL that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy and who were not deemed candidates for HDCT/HSCT based on physician’s assessment and at least one of the following criteria: age ≥ 65 years; age ≥ 18 years and Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) score ≥3; or age ≥ 18 years and prior ASCT (as 1st line consolidation). Patients received lymphodepletion with cyclophosphamide and fludarabine, followed 2 days later by axi-cel infusion at a target dose of 2 × 10^6 CAR T-cells/kg. Cytokine release syndrome (CRS) and neurological events (ICANS) were graded using the ASTCT grading system. The primary endpoint was the complete metabolic response (CMR) at 3 months from axi-cel infusion based on investigator disease assessment.

Results

Of 43 patients who underwent leukapheresis, 40 received axi-cel. Median age was 68 years (range, 49-81; 45% ≥ 70 years), 30% had HCT-CI score ≥ 3, and 52.5% were refractory to first-line treatment. Overall, 37 patients (92.5%) received bridging chemotherapy (R-GEMOX for all patients but one). Twenty-seven patients (67.5%) were refractory to bridging therapy, including 15 patients (37.5%) who experienced disease progression upon bridging therapy. Median on-study follow-up was 6.7 months. The study met its primary endpoint with a CMR at 3 months of 67.5% versus 12% expected with SOC based on historical controls (Cazelles et al, Leukemia & Lymphoma 2021). Objective response (OR) rate at 3 months was 75%. Best OR and CR rates were 92.5% and 77.5%, respectively. CRS were seen in 90% of patients, including 10% of grade 3-4. ICANS were seen in 55% of patients, including 17.5% of grade 3-4. Twelve patients (30%) patients were admitted to ICU. Six patients died: 2 due to lymphoma and 4 due to fatal adverse events (COVID-19, mucormycosis, perineal infection, and sepsis). Grade ≥ 3 prolonged cytopenias (i.e. not resolved on Day 29 after axi-cel infusion) occurred in 14 patients (35%).

Conclusions

In the ALYCANTE study, axi-cel as second-line treatment in patients with LBCL who were not deemed candidates for HDCT/HSCT appears feasible and induces high response rates. Additional exploratory analyses are ongoing, including early PET-CT at Day 14 post-infusion and ctDNA monitoring, which will be presented at the meeting. Finally, the protocol was amended to allow an expansion of 20 additional patients (for a total of 60 patients) to achieve sufficient power to compare 2 subgroups of patients based on age (≥ 70 vs < 70 years).

Disclosures: Houot: Kite/Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria; MSD: Honoraria; Takeda: Honoraria; Roche: Honoraria; Bristol-Myers Squibb/Celgene: Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees; Miltenyi: Membership on an entity's Board of Directors or advisory committees. Bachy: Roche, Gilead, ADC Therapeutics, Takeda, Novartis, Incyte: Membership on an entity's Board of Directors or advisory committees; Kite, Gilead, Novartis, Roche, Incyte, Miltenyi Biotech, Takeda, Sanofi: Honoraria; Amgen, BMS: Research Funding; Hospices Civils de Lyon: Current Employment. Cartron: Gilead, Novartis, Mylteni, Sanofi, Abbvie, Takeda, Roche, Janssen, Celgene, Novartis, Bristol Myers Squibb: Honoraria; MabQi, Ownards Therapeutics, Abbvie, Roche, Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees. Gros: Novartis: Honoraria; BMS: Honoraria; Kite/Gilead: Honoraria; Milteny: Honoraria. Morschhauser: Genmab: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genentech: Consultancy; Janssen: Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Epizyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees; Miltenyi: Membership on an entity's Board of Directors or advisory committees; Allogene therapeutics: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Gilead Sciences: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Oberic: Janssen-Cilag: Honoraria, Other; Takeda: Consultancy; Roche: Consultancy, Honoraria, Other. Gastinne: Gilead/Kite, Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings/travel, participation in a data safety monitoring board or advisory board. Feugier: Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Beigen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astra: Honoraria, Membership on an entity's Board of Directors or advisory committees. Dulery: Kite/Gilead: Other. Thieblemont: Novartis: Consultancy, Honoraria, Other: Travel Support, Research Funding; Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel Support; Incyte: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Other: Travel Support; Celgene: Consultancy, Honoraria, Other: Travel Support; AbbVie: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Other: Travel Support; Bristol Myers Squibb: Consultancy, Honoraria, Other: Travel Support. Menard: Bristol-Myers Squibb: Honoraria. Delfau: Amgen: Honoraria; Gilead: Honoraria; Celgene: Research Funding; Roche: Research Funding; Mundipharma: Other. Lemonnier: Abbvie: Other: travel support; Miltenyi: Honoraria; Kiowa: Honoraria.

*signifies non-member of ASH